Explore Joe Pierre, MD's insightful analysis of why we believe falsehoods, blending psychology and cognitive science to address misinformation's impact on society.

"childhood remembrances are always a drag if you’re Black..."

Explore the psychological interplay of love and aggression in wartime, as Freud's theories resonate with today's conflicts and relationships.

Trauma can span generations. Let's help break the cycle with these 10 steps.

Care partners for patients with schizophrenia can greatly benefit from psychoeducation provided by clinicians.

Obesity is more than a weight issue--it can be reclassified as an embodied disorder. This reflection explores how shame, bodily self-awareness, and early developmental disruptions shape the lived experience of being overweight

H. Steven Moffic, MD, explores the impact of moral injuries on psychiatrist burnout, emphasizing the need for healing and support in the profession.

NRX-100, a preservative-free ketamine, announces expanded access policy for treatment of suicidal ideation in depression, offering new hope for patients.

Black youth, particularly boys, face mischaracterization and punishment in schools.

A farewell to Max Fink, MD, who passed this June. He was a pioneer in the field of electroconvulsive therapy.

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

Dive into the forms of assessment for cognitive dysfunction in relation to the diagnosis and treatment of schizophrenia.

Read about opinions and events in firearm injury prevention among adolescents and clinicians.

Thomas Priolo, MD discusses strategies to manage back-to-school changes in child and adolescent psychiatric care.

Warren Brody, MD: Ahead of his time? Remembering his life and legacy.

Read the full, exclusive transcript from the inaugural "Brain Trust: Conversations in Clinical Psychopharmacology" video with Joseph F. Goldberg, MD, and Marlene Freeman, MD.

OpenAI acknowledges ChatGPT's risks to psychiatric patients and commits to improving safety measures, but skepticism about their sincerity remains.

Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.

Reflect on the risk artificial intelligence poses to psychiatric patients and the ethical questions that arise from this new technology.

In this CME, learn about the convergence of neuroscience and spirituality.

Most of the US population—nearly 80%—endorse spiritual and/or religious beliefs. How can these beliefs be applied to psychiatry?

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.